Bone Mass Accrual in Adolescent Athletes

Bone Loss Clinical Trial

— 838  

Official title:

"2008P-00346: Bone Mass Accrual in Adolescent Athletes"

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00827151
• Other study ID #: 2008P00246
• Secondary ID: NIH-HCNRC
• Status: Withdrawn
• Phase: Phase 3
• Start date: December 2008
• Est. completion date: January 2015

Study information

• Verified date: October 2021
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The adolescent and young adult years are a critical window in time for bone mineral accrual. More than 90% of peak bone mass is achieved by 18 years, and data indicate that insults sustained during adolescence and young adulthood may result in permanent deficits in bone accrual. Adult athletes with amenorrhea (AA) have low bone mineral density (BMD) secondary to hypogonadism, associated with increased fracture risk and associated co-morbidities. We will examine whether estrogen replacement will increase BMD and improve measures of bone microarchitecture in adolescents and young women with AA, thus optimizing peak bone mass.

Description:

Young female athletes 18-21 years old will be randomized to estrogen (and progesterone) with lifestyle modification versus lifestyle modification alone for a 12 month period. Bone density and structure will be assessed over this period. Hormonal evaluations will also be performed.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2015
• Est. primary completion date: May 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 21 Years

Eligibility

Inclusion Criteria:

• Female

• 18-21 years of age

• Hypothalamic amenorrhea

• Greater than or equal to 15 years bone age

• BMI between 10th-90th percentiles for age

Exclusion Criteria:

• Use of medications affecting bone metabolism including estrogen/ progesterone, anabolic steroids and glucocorticoids except local application of glucocorticoid creams (washout period of three months necessary prior to study enrollment if medically permissible to discontinue these)

• Presence of anorexia nervosa or %IBW of < 85% based on the 50th %ile of BMI for age

• Spine BMD Z-score < -3

• Conditions other than endurance training that may cause amenorrhea including PCOS (clinical or preceding laboratory evidence of hyperandrogenism with amenorrhea)

• Conditions other than endurance training that may cause bone metabolism to be affected

• Abnormal TSH, elevated FSH, hematocrit < 30%

• Pregnancy

For girls with AA (to be randomized to estrogen and progesterone or no treatment)

• History of migraines, hypertension, allergy to peanut oil, undiagnosed abnormal genital bleeding, known, suspected or history of breast or genital cancer or estrogen dependent neoplasia, known hypersensitivity to progesterone or estrogen or other product ingredients, liver dysfunction or disease

• LFTs greater than 1.5 times the upper limit of normal

• Family history or personal history of conditions that may increase risk of thromboembolism:

1. Family history of myocardial infarction or strokes occurring at less than 50 years

2. Family history of clotting disorders: normal coagulation profile will be necessary for enrollment

• History of smoking >10 cigarettes a day (history of smoking >14 cigarettes a day is a contraindication for estrogen, but we will be more conservative in our exclusion criteria)

• Personal history of blood clots

Related Conditions & MeSH terms

• Amenorrhea
• Bone Loss

Intervention

Drug:
• Estrogen
Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bone density		One year